HER2 inhibitors extend survival in HER2-amplified breast cancers; however, they are not sufficiently active as monotherapy1,2, unlike other receptor tyrosine kinase (RTK) inhibitors in solid tumor cancer paradigms. This evidence concerns the gene ERBB2 and breast carcinoma.